1-benzyl-2-phenylbenzimidazole profile

1-Benzyl-2-phenylbenzimidazole is a heterocyclic compound that contains a benzimidazole ring system.

**Structure:**

* It consists of a benzimidazole core, which is a five-membered ring containing two nitrogen atoms.
* A benzyl group (CH2-Ph) is attached to the nitrogen at the 1-position.
* A phenyl group (Ph) is attached to the carbon at the 2-position.

**Importance in Research:**

1-Benzyl-2-phenylbenzimidazole is of interest in research due to its potential **biological activities and applications**:

* **Anti-cancer activity:** Studies have shown that benzimidazole derivatives, including 1-benzyl-2-phenylbenzimidazole, exhibit anti-cancer properties. They can inhibit the growth and proliferation of various cancer cell lines.
* **Anti-microbial activity:** Benzimidazoles have been investigated for their potential as anti-bacterial, anti-fungal, and anti-viral agents. The specific activity of 1-benzyl-2-phenylbenzimidazole may depend on its structural modifications.
* **Ligand for metal complexes:** Benzimidazoles can act as ligands in coordination chemistry, forming complexes with various metal ions. These complexes may have applications in catalysis, materials science, and medicine.
* **Pharmacological studies:** 1-Benzyl-2-phenylbenzimidazole and related compounds are often synthesized and studied as potential drug candidates. Research focuses on identifying their pharmacokinetic and pharmacodynamic properties to evaluate their therapeutic potential.
* **Synthetic building blocks:** The benzimidazole ring system serves as a starting point for the synthesis of other biologically active molecules. This versatility makes it a valuable building block in medicinal chemistry.

**Note:** While research is ongoing, 1-benzyl-2-phenylbenzimidazole itself may not currently be used in any approved drugs or therapies.

It's important to remember that research on the biological activities of this compound is ongoing and the specific applications may still be under investigation.

1-benzyl-2-phenylbenzimidazole: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	1221687
CHEMBL ID	1922082
SCHEMBL ID	229828
MeSH ID	M000609302

Synonym
1-benzyl-2-phenyl-1h-benzimidazole
STL288023
CHEMDIV3_011388
1-benzyl-2-phenyl-1h-benzoimidazole
IDI1_028946
BRD-K09137815-001-01-9
HMS1505F14
AKOS000569392
1-benzyl-2-phenylbenzimidazole
1-benzyl-2-phenyl-1h-benzo[d]imidazole
739-88-8
2-phenyl-1-(phenylmethyl)-1h-benzimidazole
CHEMBL1922082
bdbm106769
1‐benzyl‐2‐phenyl‐1,3‐benzodiazole (b10)
4JV6
F0852-0127 ,
LCFXRSKBJWQHON-UHFFFAOYSA-N
SCHEMBL229828
1-benzyl-2-phenyl-1h-1,3-benzodiazole
DTXSID90361117
mfcd00844714
sr-01000417978
SR-01000417978-1
AS-36434
Q27451775

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Xanthine dehydrogenase/oxidase	Bos taurus (cattle)	IC50 (µMol)	9.7000	0.0030	3.1015	9.8000	AID1800155
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)	Kd	1.8217	0.0011	0.8485	2.9000	AID1154661; AID1154662; AID1455783
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
visual perception	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
xanthine catabolic process	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
GTPase inhibitor activity	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
protein binding	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
small GTPase binding	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
xanthine dehydrogenase activity	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
xanthine oxidase activity	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
iron ion binding	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
molybdenum ion binding	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
protein homodimerization activity	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
molybdopterin cofactor binding	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
flavin adenine dinucleotide binding	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
2 iron, 2 sulfur cluster binding	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
FAD binding	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
cytoskeleton	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
cilium	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
cytoplasmic vesicle membrane	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
cytoplasmic vesicle	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
cytoplasm	Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta	Homo sapiens (human)
extracellular space	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
peroxisome	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
xanthine dehydrogenase complex	Xanthine dehydrogenase/oxidase	Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay ID	Title	Year	Journal	Article
AID631839	Bactericidal activity against Bacillus cereus MTCC 430 assessed as log reduction in bacterial count at 0.2 mg/mL up to 48 hrs by time-kill assay	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents.
AID1186340	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID631841	Bactericidal activity against Vibrio cholerae MTCC 3904 assessed as time required to complete extermination of bacteria at 0.2 mg/mL by time-kill assay	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents.
AID1154661	Binding affinity to PDE-delta (unknown origin) by time-resolved fluorescence anisotropic analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
AID631837	Antibacterial activity against Bacillus cereus MTCC 430 assessed as zone of growth inhibition at 0.2 mg/ml after 18 to 24 hrs by Kirby-Bauer agar diffusion method	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents.
AID1186328	Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID631835	Antibacterial activity against Vibrio cholerae MTCC 3904 assessed as zone of growth inhibition at 0.2 mg/ml after 18 to 24 hrs by Kirby-Bauer agar diffusion method	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents.
AID1186334	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID631836	Antibacterial activity against Escherichia coli MTCC 1610 assessed as zone of growth inhibition at 0.2 mg/ml after 18 to 24 hrs by Kirby-Bauer agar diffusion method	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents.
AID1186327	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1186338	Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1186336	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID631834	Antibacterial activity against Staphylococcus aureus MTCC 3160 assessed as zone of growth inhibition at 0.2 mg/ml after 18 to 24 hrs by Kirby-Bauer agar diffusion method	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents.
AID631833	Antibacterial activity against Shigella dysenteriae assessed as zone of growth inhibition at 0.2 mg/ml after 18 to 24 hrs by Kirby-Bauer agar diffusion method	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Exploration of in vitro time point quantitative evaluation of newly synthesized benzimidazole and benzothiazole derivatives as potential antibacterial agents.
AID1186330	Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1186342	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Respiratory syncytial virus	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1231610	Cytotoxicity against HUVEC assessed as inhibition of cell proliferation rate at 10 uM after 72 hrs by MTT assay relative to control	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID1231611	Cytotoxicity against HUVEC assessed as inhibition of cell proliferation rate at 100 uM after 72 hrs by MTT assay relative to control	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID1186333	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1186339	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1186332	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1186329	Cytotoxicity against mock-infected MDBK cells after 48 to 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1154662	Binding affinity to PDE-delta (unknown origin) by SPR analysis	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
AID1687307	Antimicrobial activity against Escherichia coli JW55031 TolC mutant assessed as reduction in microbial growth incubated for 18 to 20 hrs by broth microdilution method	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria.
AID1186335	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1186337	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1186331	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1455783	Inhibition of atorvastatin PEG-fluorescein binding to PDEdelta (unknown origin) by fluorescence polarization assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1800155	XO inhibitory activity from Article 10.1111/cbdd.12141: \\In vitro evaluation of selected benzimidazole derivatives as an antioxidant and xanthine oxidase inhibitors.\\	2013	Chemical biology & drug design, Sep, Volume: 82, Issue:3	In vitro evaluation of selected benzimidazole derivatives as an antioxidant and xanthine oxidase inhibitors.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2013	Nature, May-30, Volume: 497, Issue:7451	Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	10 (90.91)	24.3611
2020's	1 (9.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.06	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
nocodazole [no description available]	2.11	1	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
benzimidazole 1H-benzimidazole : The 1H-tautomer of benzimidazole.	2.11	1	benzimidazole; polycyclic heteroarene
azauridine Azauridine: A triazine nucleoside used as an antineoplastic antimetabolite. It interferes with pyrimidine biosynthesis thereby preventing formation of cellular nucleic acids. As the triacetate, it is also effective as an antipsoriatic.	2.1	1	N-glycosyl-1,2,4-triazine	antimetabolite; antineoplastic agent; drug metabolite
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.25	1	cyclic ketone; erythromycin
2-phenylbenzimidazole 2-phenylbenzimidazole: structure in first source	7.07	1
vinblastine [no description available]	2.11	1
2-ethylbenzimidazole [no description available]	2.1	1
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.11	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
ribavirin Rebetron: Rebetron is tradename	2.1	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.1	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
gentamicin c1a [no description available]	2.25	1	gentamycin C
linezolid [no description available]	2.25	1	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	2.1	1	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.1	1	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
su 11248 [no description available]	2.11	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
fluconazole deltarasin: inhibits the interaction between PDEdelta and KRAS protein; structure in first source	2.1	1
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.1	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.08	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger

Condition	Relationship Strength	Studies
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Adenocarcinoma, Basal Cell [description not available]	2.08	1
Carcinoma, Ductal, Pancreatic [description not available]	2.08	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.08	1
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.08	1
Bone Cancer [description not available]	2.07	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.07	1
Chondrosarcoma A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)	7.07	1

1-benzyl-2-phenylbenzimidazole

Description

Cross-References

Synonyms (26)

Protein Targets (2)

Inhibition Measurements

Activation Measurements

Biological Processes (2)

Molecular Functions (12)

Ceullar Components (9)

Bioassays (32)

Research

Studies (11)

Market Indicators

Research Demand Index: 13.21

Study Types

1-benzyl-2-phenylbenzimidazole

Description

Cross-References

Synonyms (26)

Protein Targets (2)

Inhibition Measurements

Activation Measurements

Biological Processes (2)

Molecular Functions (12)

Ceullar Components (9)

Bioassays (32)

Research

Studies (11)

Market Indicators

Research Demand Index: 13.21

Study Types

Related Drugs (19)

Related Conditions (9)